Literature DB >> 15080414

Bullous mastocytosis treated with oral betamethasone therapy.

Kaushal K Verma1, Radhakrishna Bhat, Manoj K Singh.   

Abstract

Bullous mastocytosis is a very rare variant of cutaneous mastocytosis. The condition is characterized by a diffuse infiltration of the skin by mast cells manifesting as yellowish, thickened doughy skin with appearance of large blisters. The authors report herewith a 7-month-old female infant with history of recurrent episodes of vesiculobullous lesions on the face, trunk and the extremities and excessive tendency to rub and scratch the skin for 3 months. She also had recurrent episodes of facial flushing. On cutaneous examination there were multiple flaccid bullae, urticarial wheals and crusted erosions on her scalp, face, neck, trunk and extremities. She had generalised yellowish thick and rough skin, giving doughy feel and 'peau d' orange' appearance of the skin at places. Systemic examination was within normal limits. Skin biopsy from a lesion showed subepidermal bulla and an upper dermal inflammatory infiltrate comprising of lymphocytes and many mast cells. Toluidine blue staining of the cells showed presence of metachromatic granules in these cells. A diagnosis of bullous mastocytosis was made and the patient was treated with oral antihistamines to which there was no satisfactory response. Betamethasone in a dose of 0.1 mg/kg/day given orally caused complete remission of the disease in 4 weeks. The drug was gradually tapered and stopped over the next 6 weeks. There were no side effects of the therapy.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15080414     DOI: 10.1007/bf02724280

Source DB:  PubMed          Journal:  Indian J Pediatr        ISSN: 0019-5456            Impact factor:   1.967


  15 in total

1.  Oral disodium cromoglycate in the treatment of systemic mastocytosis.

Authors:  N A Soter; K F Austen; S I Wasserman
Journal:  N Engl J Med       Date:  1979-08-30       Impact factor: 91.245

2.  DIFFUSE CUTANEOUS MASTOCYTOSIS.

Authors:  R P WARIN; R C HUGHES
Journal:  Br J Dermatol       Date:  1963-07       Impact factor: 9.302

Review 3.  Bullous mastocytosis: a fatal outcome.

Authors:  M Murphy; D Walsh; B Drumm; R Watson
Journal:  Pediatr Dermatol       Date:  1999 Nov-Dec       Impact factor: 1.588

4.  Congenital bullous mastocytosis with myeloproliferative disorder and c-kit mutation.

Authors:  P Y Shah; V Sharma; A S Worobec; D D Metcalfe; D C Zwick
Journal:  J Am Acad Dermatol       Date:  1998-07       Impact factor: 11.527

5.  Diffuse cutaneous mastocytosis. Treatment with oral psoralen plus UV-A.

Authors:  S Mackey; H B Pride; W B Tyler
Journal:  Arch Dermatol       Date:  1996-12

6.  Bullous mastocytosis in an infant associated with the use of a nonprescription cough suppressant.

Authors:  J Cook; M Stith; E E Sahn
Journal:  Pediatr Dermatol       Date:  1996 Sep-Oct       Impact factor: 1.588

Review 7.  Interferon-alpha in combination with corticosteroids improves systemic mast cell disease.

Authors:  E Delaporte; E Piérard; B G Wolthers; P Desreumaux; A Janin; A Cortot; F Piette; H Bergoend
Journal:  Br J Dermatol       Date:  1995-03       Impact factor: 9.302

Review 8.  Mastocytosis: recent advances in defining the disease.

Authors:  K Hartmann; B M Henz
Journal:  Br J Dermatol       Date:  2001-04       Impact factor: 9.302

9.  Treatment of urticaria pigmentosa with corticosteroids.

Authors:  J Barton; R M Lavker; N M Schechter; G S Lazarus
Journal:  Arch Dermatol       Date:  1985-12

10.  Photochemotherapy (PUVA) in the treatment of urticaria pigmentosa.

Authors:  D Vella Briffa; R A Eady; M P James; S Gatti; S S Bleehen
Journal:  Br J Dermatol       Date:  1983-07       Impact factor: 9.302

View more
  2 in total

Review 1.  Staphylococcal-scalded skin syndrome: evaluation, diagnosis, and management.

Authors:  Alexander K C Leung; Benjamin Barankin; Kin Fon Leong
Journal:  World J Pediatr       Date:  2018-03-05       Impact factor: 2.764

2.  Cutaneous Mastocytosis with Persistent Blistering: Successful Treatment with Methylprednisolone and 3-Year Follow-Up Management.

Authors:  Rumyana Yankova; Tsvetana Abadjieva; Veselin Belovezhdov
Journal:  Dermatol Ther (Heidelb)       Date:  2015-04-15
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.